<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute cervicitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute cervicitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute cervicitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna Maya Powell, MD MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Nyirjesy, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeanne Marrazzo, MD, MPH, FACP, FIDSA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 23, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cervicitis refers to inflammation of the uterine cervix. The inflammation primarily affects the columnar epithelial cells of the endocervical glands but can also affect the squamous epithelium of the ectocervix. It may be due to an infectious or noninfectious etiology and may be acute or chronic. Acute cervicitis is often due to infection (eg, chlamydia, gonorrhea), although a specific infection cannot be determined in a large proportion of cases. Chronic cervicitis usually has a noninfectious source.</p><p>This topic will review the background, evaluation, diagnosis, and management of acute cervicitis in postpubertal and adult females. Related discussions of vaginitis (in adults and children) and endometritis are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5477.html" rel="external">"Vaginitis in adults: Initial evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/134115.html" rel="external">"Vulvovaginitis in the prepubertal child: Clinical manifestations, diagnosis, and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5462.html" rel="external">"Endometritis unrelated to pregnancy"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use "woman/en" as used in the studies presented. However, we encourage the reader to consider the specific counseling and treatment needs of transgender and gender-diverse individuals.</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY AND ETIOLOGY</span></p><p class="headingAnchor" id="H2857450374"><span class="h2">Prevalence estimates</span><span class="headingEndMark"> — </span>The exact prevalence of cervicitis is difficult to define because there is no standard definition or case reporting among studies, and the prevalence likely varies by population. In sexually transmitted infection (STI) clinics, it may affect as many as 30 to 45 percent of patients [<a href="#rid1">1,2</a>]. Sexual activity is the main risk factor as it is a risk factor for the causative infections. It is helpful for clinicians to know the STI prevalence rates for their communities. (See <a class="local">'Infectious etiologies'</a> below.)</p><p class="headingAnchor" id="H19001049"><span class="h2">Infectious etiologies</span><span class="headingEndMark"> — </span>An infectious etiology can be suspected when a specific organism associated with cervicitis, including sexually transmitted ones discussed below, is identified.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Most common</strong> – When an infectious etiology can be documented, <em>Chlamydia trachomatis</em> (typically serovars D-K) and <em>Neisseria gonorrhoeae</em> are the most common organisms identified [<a href="#rid3">3</a>], even though only a relatively small proportion of individuals with these infections develops cervicitis. Chlamydial cervicitis occurs more often than gonococcal, and both primarily affect the columnar epithelium of the endocervix. Combined, these infections account for approximately 50 percent of cases of cervicitis [<a href="#rid4">4-6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common</strong> – Other infectious etiologies include herpes simplex virus (HSV), <em>Mycoplasma genitalium</em>, <em>Trichomonas vaginalis</em>, which primarily affect the squamous epithelium of the ectocervix [<a href="#rid3">3,7-10</a>]. Bacterial vaginosis (BV) and streptococci (group A) have also been implicated as causative agents of acute cervicitis [<a href="#rid1">1,11,12</a>]. BV is unlikely to be a cause of isolated cervicitis without concurrent vaginal findings. Tuberculosis involves the cervix in a small proportion of females with tuberculous endometritis [<a href="#rid13">13,14</a>] (see  <a class="medical medical_review" href="/z/d/html/5462.html" rel="external">"Endometritis unrelated to pregnancy", section on 'Tuberculous endometritis'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uncommon</strong> – Case reports have described cervicitis associated with other infectious agents (bacteria, viruses, fungi, parasites) [<a href="#rid2">2,15-23</a>]. Although<em> Mycoplasma hominis</em>, <em>Ureaplasma urealyticum</em>, cytomegalovirus, and group B beta-hemolytic streptococci are commonly found in the genital tract, there is little evidence that they independently cause cervicitis [<a href="#rid24">24-26</a>].</p><p></p><p class="bulletIndent1">There is no evidence that human papillomavirus infection induces cervical inflammation, but it can cause other histologic changes (eg, cervical intraepithelial neoplasia). However, organisms involved in cervicitis may act as potential cofactors (not direct cause) in development of cervical neoplasia (eg, <em>U. urealyticum</em>) [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/8031.html" rel="external">"Virology of human papillomavirus infections and the link to cancer"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3216.html" rel="external">"Cervical intraepithelial neoplasia: Terminology, incidence, pathogenesis, and prevention"</a>.)</p><p></p><p class="headingAnchor" id="H19001056"><span class="h2">Noninfectious causes</span><span class="headingEndMark"> — </span>In cases where no infection is identified, cervicitis is usually caused by mechanical or chemical irritation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common</strong> – Sources of mechanical irritation include trauma from surgical instruments or foreign objects (eg, pessary, diaphragm, tampon, cervical cap, or condom). Chemical irritation can be caused by exposure to latex, vaginal douches, spermicides, or contraceptive creams. Commercial products may also contain irritating ingredients such as povidone-iodine, surfactants, topical anesthetics, or cornstarch [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Less common</strong> – Less common noninfectious causes include radiation therapy and systemic inflammatory diseases such as Behçet syndrome or lichen planus. In hypoestrogenic females, desquamative inflammatory vaginitis can cause inflammation of the cervix along with a more diffuse vaginal inflammation; in these cases, the purulent discharge comes from both the cervix and vagina. (See  <a class="medical medical_review" href="/z/d/html/5454.html" rel="external">"Desquamative inflammatory vaginitis (DIV)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rare</strong> – Rare causes of noninfectious cervicitis documented in case reports include congenital plasminogen deficiency with resultant ligneous lesions of the cervix, cystic cervicitis, small cell carcinoma, and lymphoma [<a href="#rid29">29-31</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Cervicitis is diagnosed clinically. Individuals with cervicitis may have presenting symptoms or be asymptomatic, in which case the diagnosis is made at the time of physical examination for other indications. In an observational study that included 59 women presenting for routine cervical cancer screening, 24 percent had signs of cervicitis on examination, but only 5 percent had symptoms (vaginal discharge) [<a href="#rid4">4</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Characteristic symptoms include either or both [<a href="#rid3">3,5</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Purulent or mucopurulent (yellow) endocervical exudate that is visible either in the endocervical canal or on an endocervical swab</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endocervical bleeding that is easily caused by gently passing an endocervical swab through the cervical os</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional symptoms or signs can include [<a href="#rid2">2,32</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dysuria, urinary frequency</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dyspareunia</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vulvovaginal irritation</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Edema of the cervical ectropion </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Postcoital bleeding</p><p></p><p>Urinary symptoms are generally due to concomitant urethritis, which occurs in approximately 15 percent of females with cervical chlamydia infection. Pain and fever are atypical in the absence of upper tract infection (endometritis, pelvic inflammatory disease [PID]) or herpes simplex virus (HSV) infection.</p><p class="headingAnchor" id="H350769532"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H798499184"><span class="h2">History</span><span class="headingEndMark"> — </span>Evaluation of patient risk factors is important and should include a detailed discussion of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fstd%2Ftreatment%2Fsexualhistory.pdf&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLMtWRdy7GNFvGuwQhc910NNT9ipDp%2BKwqfFBJOW0qsq%2B8VPZboi5b11NBx3hoCSliQ%3D%3D&amp;TOPIC_ID=5460" target="_blank">sexual history</a> (number of partners, condom use, type of sexual activity, new sex partner, sex partner with concurrent sex partners, sex partner with a sexually transmitted infection [STI]), vaginal hygiene (douching), and age (&lt;25). Clinicians should be aware of STI prevalence in their communities. Factors associated with noninfectious cervicitis are listed above. (See <a class="local">'Noninfectious causes'</a> above.)</p><p>To generate a complete differential diagnosis, we also inquire about:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaginal discharge</strong> – The typical discharge of cervicitis is purulent or mucopurulent (yellow). By contrast, the vaginal discharge usually associated with bacterial vaginosis (BV) is gray or off-white and malodorous, with vulvovaginal candidiasis scant and thick and with trichomoniasis brownish or bloody and malodorous.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaginal bleeding</strong> – Patients with cervicitis often present with intermenstrual or postcoital vaginal bleeding. We ask about symptoms in relation to timing of vaginal sexual activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Burning, irritation, or other local discomfort</strong> – Isolated cervicitis is typically painless. However, coexisting vaginal infections with <em>Candida</em> species may result in itching while BV may result in minor irritative symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abdominal or pelvic pain</strong> – Cervicitis alone generally does not cause pelvic or abdominal pain. However, patients with associated endometritis or pelvic inflammatory disease (PID) often complain of pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of symptoms</strong> – Symptoms of <em>Candida vulvovaginitis</em> often occur in the premenstrual period, while symptoms of trichomoniasis and BV often occur during or immediately after the menstrual period. Symptoms of cervicitis typically do not follow any specific time pattern.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Estrogen status</strong> – Individuals with genitourinary syndrome of menopause (GSM) can present with symptoms similar to cervicitis. Common additional findings of GSM include tissue fragility, labial resorption, and decrease or loss of vaginal rugae and secretions. (See  <a class="medical medical_review" href="/z/d/html/5464.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Clinical manifestations and diagnosis", section on 'Clinical presentation'</a>.)</p><p></p><p>Discussion of patient history that is suggestive of <em>Candida vulvovaginitis</em>, BV, and trichomoniasis is presented elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5452.html" rel="external">"Candida vulvovaginitis: Clinical manifestations and diagnosis", section on 'Symptoms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5451.html" rel="external">"Bacterial vaginosis: Clinical manifestations and diagnosis", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5453.html" rel="external">"Trichomoniasis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5453.html" rel="external">"Trichomoniasis: Clinical manifestations and diagnosis", section on 'Female'</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>All patients with symptoms suggestive of cervicitis undergo a physical examination that includes pelvic and vaginal evaluations  (<a class="graphic graphic_algorithm graphicRef138432" href="/z/d/graphic/138432.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H2869638254"><span class="h3">Hallmark findings</span><span class="headingEndMark"> — </span>The classic findings at the time of speculum examination are (1) a purulent/mucopurulent discharge on the ectocervix or exuding from the endocervical canal  (<a class="graphic graphic_picture graphicRef67848" href="/z/d/graphic/67848.html" rel="external">picture 1</a>) or (2) bleeding upon touching the cervix with a cotton or Dacron swab (ie, friability) [<a href="#rid3">3</a>]. However, these findings are not diagnostic of etiology [<a href="#rid33">33</a>].</p><p>In infection-related cases, the cervical appearance varies with the type of infecting organism and severity of infection. The quantity of cervical organisms correlates with the degree of inflammation.</p><p class="bulletIndent1"><span class="glyph">●</span>Mucopurulent cervical discharge, cervical friability, and edema in the zone of ectopy are characteristic of both gonococcal and chlamydial cervicitis  (<a class="graphic graphic_picture graphicRef94345" href="/z/d/graphic/94345.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef67848" href="/z/d/graphic/67848.html" rel="external">picture 1</a>). The presence of one or more of these signs is more predictive of gonorrhea or chlamydia infection in younger compared with older women (1 in 3 women &lt;25 years infected versus 1 in 6 to 11 women &gt;25 years) [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Punctate hemorrhages ("strawberry cervix" or colpitis macularis) are characteristic of <em>T. vaginalis</em> infection  (<a class="graphic graphic_picture graphicRef102398" href="/z/d/graphic/102398.html" rel="external">picture 3</a>). Erosive inflammation can also be present. (See  <a class="medical medical_review" href="/z/d/html/5453.html" rel="external">"Trichomoniasis: Clinical manifestations and diagnosis", section on 'Female'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse vesicular lesions/ulceration, which may include sloughing of the epithelium, suggest herpes simplex virus (HSV) infection  (<a class="graphic graphic_picture graphicRef58485" href="/z/d/graphic/58485.html" rel="external">picture 4</a>). Erosive inflammation can occur as well. Primary HSV infection is often associated with systemic symptoms as well. Subclinical HSV shedding is not typically associated with cervicitis [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/8347.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection"</a>.)</p><p></p><p>The clinical features of cervicitis caused by <em>M. genitalium</em> are not well-defined; some studies suggest that the majority of cervical infections with this possible pathogen do not elicit visible signs of inflammation [<a href="#rid9">9,35,36</a>]. It is not generally possible to distinguish infectious from noninfectious acute cervicitis by physical examination. (See <a class="local">'Recurrent or persistent disease'</a> below.)</p><p>In any person with suspected cervicitis, visual evaluation of the cervix should be followed by bimanual examination of the pelvic organs to exclude PID. (See  <a class="medical medical_review" href="/z/d/html/7581.html" rel="external">"Pelvic inflammatory disease: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H2496753164"><span class="h3">Alarm findings</span><span class="headingEndMark"> — </span>Patients meeting criteria for PID (cervical motion tenderness <strong>or</strong> uterine tenderness <strong>or</strong>_ adnexal tenderness) in addition to cervicitis should be evaluated and treated appropriately. Most patients with PID have either mucopurulent cervical discharge or leukorrhea on <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> preparation of vaginal fluid [<a href="#rid3">3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7581.html" rel="external">"Pelvic inflammatory disease: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7585.html" rel="external">"Pelvic inflammatory disease: Treatment in adults and adolescents"</a>.)</p><p></p><p>Individuals with erosive cervical lesions suggestive of cancer should be further evaluated with Pap smear, colposcopy, cervical biopsy, and referral to a gynecologic oncologist as needed. (See  <a class="medical medical_review" href="/z/d/html/3179.html" rel="external">"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H638931"><span class="h2">Laboratory evaluation</span><span class="headingEndMark"> — </span>If cervicitis is suspected based on cervical examination findings, further evaluation should be performed to determine the cause and exclude STIs [<a href="#rid3">3</a>]. We routinely evaluate all patients with suspected cervicitis for <em>C. trachomatis</em>, <em>N. gonorrhoeae,</em> trichomoniasis, and BV [<a href="#rid3">3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaginal pH and </strong><a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a><strong> microscopy</strong> – As individuals with cervicitis may also have concurrent vaginitis, we perform vaginal pH and saline microscopy. Presence of polymorphonuclear cells on microscopy suggests of vaginal and/or cervical infection; absence of such cells suggests alternate etiologies  (<a class="graphic graphic_table graphicRef68759" href="/z/d/graphic/68759.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/5477.html" rel="external">"Vaginitis in adults: Initial evaluation", section on 'Test vaginal discharge'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing for chlamydia and gonorrhea</strong> – We advise nucleic acid amplification testing (NAAT) for <em>N. gonorrhoeae</em> and <em>C. trachomatis</em>. These assays can be performed on a swab of vaginal fluid, an endocervical sample (cells are obtained by rotating a swab within the endocervical canal while applying gentle lateral pressure), or, if a speculum examination is not possible, on urine [<a href="#rid3">3</a>]. Application of NAAT to these samples has excellent performance relative to that for direct endocervical sampling. (See  <a class="medical medical_review" href="/z/d/html/15893.html" rel="external">"Clinical manifestations and diagnosis of <i>Neisseria gonorrhoeae </i>infection in adults and adolescents", section on 'Nucleic acid amplification'</a> and  <a class="medical medical_review" href="/z/d/html/83019.html" rel="external">"Clinical manifestations and diagnosis of <i>Chlamydia trachomatis </i>infections", section on 'Nucleic acid amplification testing (test of choice)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing for BV and trichomoniasis</strong> – <em>T. vaginalis</em> may cause isolated cervicitis; BV typically affects the vagina  (<a class="graphic graphic_table graphicRef68759" href="/z/d/graphic/68759.html" rel="external">table 1</a>). Either infection may occur concurrently with cervicitis. Microscopy (wet prep), the amine (whiff) test, and vaginal pH are useful for identifying BV. The sensitivity of microscopy to detect <em>T. vaginalis</em> is relatively low (approximately 50 percent); therefore, symptomatic individuals with cervicitis and negative microscopy for trichomonads should undergo further testing, preferably NAAT. NAAT offers a more sensitive means of detection than the other options and can be performed on the same screening specimen used for chlamydia and gonorrhea testing. (See  <a class="medical medical_review" href="/z/d/html/5451.html" rel="external">"Bacterial vaginosis: Clinical manifestations and diagnosis", section on 'Diagnostic evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/5453.html" rel="external">"Trichomoniasis: Clinical manifestations and diagnosis", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing for </strong><strong><em>M. genitalium</em></strong> – Some experts suggest testing patients with cervicitis with an <em>M. genitalium</em> NAAT, if available, particularly in patients with cervicitis that does not respond to empiric treatment for gonorrhea and chlamydia. NAATs are the only clinically useful method of detecting <em>M. genitalium</em> on urogenital specimens. (See  <a class="medical medical_review" href="/z/d/html/83202.html" rel="external">"<i>Mycoplasma genitalium</i> infection", section on 'Diagnosis'</a>.) </p><p></p><p>Routinely testing for infections other than <em>T. vaginalis</em>, gonorrhea, chlamydia, <em>M. genitalium</em>, and BV is not useful unless a specific organism, such as HSV, is suspected. There is generally no role for other bacterial cultures (eg, general vaginal culture) or polymerase chain reaction, which can be very costly and often detects vaginal bacteria that are unrelated to the cervical process. (See  <a class="medical medical_review" href="/z/d/html/8347.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection"</a>.)</p><p class="headingAnchor" id="H30962963"><span class="h2">Unnecessary tests</span><span class="headingEndMark"> — </span>While Gram stain and histopathology/cytology can be performed, we do not find these tests helpful in evaluating patients with findings of cervicitis on physical examination. </p><p class="bulletIndent1"><span class="glyph">●</span>Gram stain – For Gram stain, while the presence of &gt;10 polymorphonuclear cells per oil immersion field (ie, high power field) is indicative of mucopurulent cervicitis and suggests chlamydial or gonococcal infection, this information is of limited value since a specific diagnosis requires identification of an organism [<a href="#rid33">33</a>]. In addition, the criterion for elevated number of polymorphonuclear cells in cervical exudate has not been standardized [<a href="#rid3">3</a>]. While the absence of leukorrhea in vaginal fluid (ie, &gt;10 polymorphonuclear cells per oil immersion field) may help exclude cervicitis, more data are needed [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histopathology or cytology – Histopathology/cytology is unnecessary in diagnostic evaluation of cervicitis, although cervical dysplasia can be associated with abnormal cervical bleeding. If performed, acute disease is characterized by stromal edema, vascular congestion, and a predominance of neutrophils in the inflammatory infiltrate. Chronic disease is characterized by an inflammatory infiltrate predominantly of round cells (lymphocytes, plasma cells, histiocytes); squamous metaplasia is common, and stromal fibrosis and granulation tissue may be present.</p><p></p><p class="headingAnchor" id="H1064140447"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of acute cervicitis is clinical and, based upon the presence of purulent or mucopurulent cervical exudate or sustained endocervical bleeding (friability), easily induced by gently touching the area with a swab [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H3972609970"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Individuals with signs or symptoms of cervicitis are evaluated for other processes that can present with cervicitis as one component.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Most common</strong> – The most common differential diagnoses are sexually transmitted infections (STIs; gonorrhea, chlamydia, trichomoniasis, herpes simplex virus (HSV) 1 or 2 infection, <em>M. genitalium</em>) and bacterial vaginosis (BV) [<a href="#rid18">18</a>]. Cervical ectropion, commonly seen in adolescent females, individuals using estrogen-containing contraceptives, and pregnant persons, can mimic acute cervicitis. (See  <a class="medical medical_review" href="/z/d/html/5428.html" rel="external">"Benign cervical lesions and congenital anomalies of the cervix", section on 'Ectropion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Less common</strong> – Those whose testing for infection is negative are evaluated for contact dermatitis, dermatoses such as lichen planus, and desquamatory inflammatory vaginitis (DIV). The approach to evaluation is the same for cervical presentations of these entities as vaginal/vulvar presentations.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Contact dermatitis or allergy</strong> (See  <a class="medical medical_review" href="/z/d/html/5477.html" rel="external">"Vaginitis in adults: Initial evaluation", section on 'No diagnosis after initial evaluation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vulvar lichen planus</strong> – Lichen planus is an inflammatory dermatologic condition that most commonly occurs in females aged 50 to 60 years  (<a class="graphic graphic_picture graphicRef96570" href="/z/d/graphic/96570.html" rel="external">picture 5</a>). (See  <a class="medical medical_review" href="/z/d/html/5557.html" rel="external">"Vulvar lichen planus"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Desquamative inflammatory vaginitis</strong> <strong>(DIV)</strong> – DIV is a noninfectious inflammatory vaginitis. Patients with DIV typically have a high vaginal pH, negative amine test, and <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> wet mount microscopy shows an increased number of parabasal and inflammatory cells, with a leukocyte to epithelial cell ratio greater than 1:1  (<a class="graphic graphic_picture graphicRef77244" href="/z/d/graphic/77244.html" rel="external">picture 6</a>) [<a href="#rid37">37,38</a>]. (See  <a class="medical medical_review" href="/z/d/html/5454.html" rel="external">"Desquamative inflammatory vaginitis (DIV)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rare</strong> – Isolated cervicitis related to hypoestrogenism alone (ie, no infection) is unusual. Postmenopausal individuals may have cervicitis as a result of their hypoestrogenic status but typically have findings of atrophic vaginitis as well. (See  <a class="medical medical_review" href="/z/d/html/5464.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The goals of treatment are relief of symptoms and prevention of infection of the upper genital tract.</p><p class="headingAnchor" id="H3417342038"><span class="h2">Rationale for treatment</span><span class="headingEndMark"> — </span>Cervicitis is treated, often before test results are available, because infectious cervicitis can result in additional problems, including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ascending infection</strong> – Some cervical infections can ascend and cause endometritis or pelvic inflammatory disease (PID) [<a href="#rid3">3</a>]. Sequelae of PID include chronic pelvic pain, infertility, and an increased risk of ectopic pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sexual transmission</strong> – The pathogens can be transmitted to sexual partners.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased susceptibility to HIV infection</strong> – Cervicitis appears to be associated with a significant increase in risk of HIV-1 acquisition and shedding [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5469.html" rel="external">"Pelvic inflammatory disease: Long-term complications"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/16612.html" rel="external">"HIV infection: Risk factors and prevention strategies", section on 'Sexually transmitted infections'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy complications</strong> – In pregnant persons, it may cause pregnancy or neonatal complications, including preterm birth and low birth weight, as a result of infection of the fetus, placenta, amniotic fluid, decidua, or membrane  (<a class="graphic graphic_table graphicRef63047" href="/z/d/graphic/63047.html" rel="external">table 2</a>) [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/6761.html" rel="external">"Spontaneous preterm birth: Overview of risk factors and prognosis", section on 'Infection'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5062.html" rel="external">"Infants with fetal (intrauterine) growth restriction", section on 'Pathophysiology and etiology'</a>.)</p><p></p><p class="headingAnchor" id="H318766922"><span class="h2">Treatment approaches</span><span class="headingEndMark"> — </span>Individuals with clinically diagnosed cervicitis are offered treatment regardless of symptomatology. The goals of treatment are relief of symptoms and prevention of infection of the upper genital tract. Patients can be offered empiric therapy (ie, treat without waiting for test results), treatment based on the risk of having a sexually transmitted infection (STI), or targeted therapy (ie, infection-focused treatment as determined by test results). As studies comparing the approaches are lacking, all approaches are reasonable and patient preferences influence the decision.</p><p class="headingAnchor" id="H533159390"><span class="h3">Empiric therapy</span><span class="headingEndMark"> — </span>We suggest that patients with cervicitis receive empiric antibiotic therapy at the time of initial evaluation, without waiting for results of laboratory tests, especially if demographic and/or behavioral risk is consistent with STI acquisition, follow-up is uncertain, if nucleic acid amplification testing (NAAT) is not available, or if a relatively insensitive diagnostic test is used in place of NAAT [<a href="#rid3">3</a>]. We provide empiric treatment that covers both gonorrhea and chlamydia infections because these are the most common infectious etiologies of cervicitis [<a href="#rid3">3</a>]. (See <a class="local">'Targeted treatment of specific infections'</a> below.)</p><p class="headingAnchor" id="H1564834466"><span class="h3">Treatment based on STI risk</span><span class="headingEndMark"> — </span>The decision for treatment can be made based on the individual's risk of acquiring an STI. While using STI risk assessment to influence treatment decision is common practice, solely using this approach to make treatment decisions has not been vetted with prospective trials. Limitations include potential limited accuracy of the patient's sexual history and the clinician's need to know local disease prevalence rates.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk of STI acquisition </strong>– Treatment should be offered to individuals at high risk of STI acquisition [<a href="#rid3">3</a>]. High-risk status includes individuals age &lt;25 years and/or those with a new sex partner, a sex partner with concurrent sex partners, or a sex partner with a known STI. Presumptive treatment includes coverage of both chlamydia and gonorrhea infections.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chlamydia</strong> – The minimum empiric regimen should include coverage of chlamydia, especially for females ≤25 years old, as the prevalence of this infection is highest in this age group. Other risk factors for chlamydia are history of a previous chlamydial infection in the prior several months, new or more than one sexual partner, and inconsistent use of condoms.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See <a class="local">'Targeted treatment of specific infections'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/z/d/html/89490.html" rel="external">"Epidemiology of <i>Chlamydia trachomatis</i> infections"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gonorrhea</strong> – We follow the Centers for Disease Control and Prevention's (CDC) Sexually Transmitted Diseases Treatment Guidelines and add therapy for gonorrhea if either the patient's risk is high or if the local prevalence of gonorrhea infection is high [<a href="#rid3">3,40</a>]. The threshold prevalence that defines "high" is not clear, but most experts agree that &gt;5 percent is reasonable, given the consequences of untreated infection and the ease with which treatment can be accomplished (ie, single-dose therapy) [<a href="#rid2">2,3</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See <a class="local">'Targeted treatment of specific infections'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/z/d/html/7587.html" rel="external">"Epidemiology and pathogenesis of <i>Neisseria gonorrhoeae</i> infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low risk of STI acquisition</strong> – Individuals at low risk for having an STI have the option of empiric treatment (coverage for both chlamydia and gonorrhea) or waiting for test results to determine treatment decisions. Even for those at low risk of STIs, empiric antibiotic therapy is reasonable if patient follow-up of test results is a concern or the local prevalence of gonorrhea or chlamydia infection is high [<a href="#rid3">3</a>]. We take this approach and generally treat low-risk individuals for both infections as well. We discuss that empiric treatment is not diagnostic for infection.</p><p></p><p class="headingAnchor" id="H19001337"><span class="h3">Targeted treatment of specific infections</span><span class="headingEndMark"> — </span>In this approach, treatment decisions are deferred until the laboratory and microscopy results are available. Findings guide targeted therapy. Individuals who are diagnosed with chlamydia, gonorrhea, or trichomoniasis infection are also offered partner evaluation and/or therapy as well as reevaluated three months after treatment [<a href="#rid3">3</a>]. (See <a class="local">'Sexual partners'</a> below and <a class="local">'Counseling and follow-up'</a> below.)</p><p>Treatment of these infections is indicated for relief of symptoms, to prevent transmission to uninfected sexual partners, and to prevent upper genital tract disease (endometritis, PID) and its sequelae. If more than one infection is identified (eg, chlamydial cervicitis and bacterial vaginosis [BV]), all should be treated. (See  <a class="medical medical_review" href="/z/d/html/5462.html" rel="external">"Endometritis unrelated to pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/7585.html" rel="external">"Pelvic inflammatory disease: Treatment in adults and adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chlamydia</strong> – Treatment options include [<a href="#rid3">3,32</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preferred</strong> – <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> 100 mg orally twice daily for seven days. This regimen is preferred for individuals with confirmed or suspected gonorrhea coinfection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alternatives</strong> – If <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> is not available or not tolerated, alternative treatment options include <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> 1 g orally once or <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> 500 mg orally daily for seven days.</p><p></p><p class="bulletIndent1">Detailed discussion of chlamydia treatment, coinfections, and special populations is found separately. (See  <a class="medical medical_review" href="/z/d/html/7579.html" rel="external">"Treatment of <i>Chlamydia trachomatis</i> infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gonorrhea </strong>– We follow the CDC guidelines for treatment and use <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> as a single intramuscular dose determined by the patient's weight [<a href="#rid3">3,40</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Weight &lt;150 kg – <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">Ceftriaxone</a> 500 mg intramuscularly once</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Weight ≥150 kg (300 lbs) – <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">Ceftriaxone</a> 1 g intramuscularly once</p><p></p><p class="bulletIndent1">If chlamydia testing is positive or if chlamydia-specific test results are not available, the patient is also treated with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg orally twice a day for seven days [<a href="#rid3">3,40</a>]. If a chlamydia-specific test has been performed and is negative, then doxycycline treatment is not needed.</p><p></p><p class="bulletIndent1">For treatment of gonorrhea, fluoroquinolones and <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> are not appropriate alternatives because of increasing resistance to these drugs, nor is therapy with oral <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> alone [<a href="#rid3">3,40,41</a>]. (See  <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Preferred regimen'</a>.)</p><p></p><p class="bulletIndent1">The management of the penicillin-allergic patient depends on the clinical suspicion of true allergy and the type of allergy (eg, morbilliform rash versus immunoglobulin E [IgE]-mediated reactions, such as urticaria). Treatment of patients with drug allergies and antibiotic resistance is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Alternate regimens'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>M. genitalium</em></strong> – If the organism is identified by laboratory testing, two-stage treatment is advised and is ideally based on results from drug-resistance testing, if available [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/83202.html" rel="external">"<i>Mycoplasma genitalium</i> infection", section on 'Regimen selection for M. genitalium'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bacterial vaginosis</strong> – Oral or topical medication may be used  (<a class="graphic graphic_table graphicRef77648" href="/z/d/graphic/77648.html" rel="external">table 3</a>). Treatment of sexual partners is not required. The presentation, diagnosis, and management of patients with BV is discussed in detail in related content.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5451.html" rel="external">"Bacterial vaginosis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/113103.html" rel="external">"Bacterial vaginosis: Initial treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>T. vaginalis</em></strong> – Females with <em>T. vaginalis</em> are treated with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 500 mg orally twice daily for seven days [<a href="#rid3">3</a>]. An alternative option is <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a> as a single oral dose of 2 g (four 500 mg tablets). Sexual partners should be treated. (See  <a class="medical medical_review" href="/z/d/html/5453.html" rel="external">"Trichomoniasis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herpes simplex virus</strong> – Treatment options for the first episode of herpes simplex virus (HSV) infection include [<a href="#rid3">3</a>] (see  <a class="medical medical_review" href="/z/d/html/8346.html" rel="external">"Treatment of genital herpes simplex virus infection"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">Acyclovir</a> – 400 mg orally three times per day for 7 to 10 days</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">Famciclovir</a> – 250 mg orally three times daily for 7 to 10 days</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">Valacyclovir</a> – 1000 mg orally twice daily for 7 to 10 days</p><p></p><p class="headingAnchor" id="H1079405644"><span class="h2">No identifiable pathogen</span><span class="headingEndMark"> — </span>Management of cervicitis in which an infectious agent has not been identified during the diagnostic evaluation is controversial, although this is a common clinical scenario. Data are sparse, and there is no strong evidence to justify suggesting one treatment approach over another [<a href="#rid17">17,42,43</a>].</p><p>We take the following approach:</p><p class="bulletIndent1"><span class="glyph">●</span>If testing for infectious etiologies is negative, the patient has not received any antimicrobial treatment, and the cervicitis has not resolved at a follow-up visit, we offer one course of antibiotic therapy with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg orally twice daily for seven days. (See <a class="local">'Empiric therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If antimicrobial therapy has been given but cervicitis symptoms persist, we repeat testing for infectious etiologies and exclude noninfectious causes. Noninfectious causes can include foreign body irritation (eg, diaphragm), chemical irritation (eg, douching), cervical dysplasia, and/or idiopathic inflammation of the cervical ectropion [<a href="#rid3">3</a>]. Any identified infections are treated as per guidelines. (See <a class="local">'Targeted treatment of specific infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If symptoms and clinical findings of acute cervicitis persist for more than three months despite antibiotics and other causes have been excluded, the patient is diagnosed with persistent noninfectious cervicitis. Management of these patients is discussed below. (See <a class="local">'Recurrent or persistent disease'</a> below.)</p><p></p><p class="headingAnchor" id="H3500061261"><span class="h2">Incidental finding on histology or cytology</span><span class="headingEndMark"> — </span>Cervicitis can be diagnosed at the time of cervical biopsy or Pap testing. In general, these patients do not require antibiotic treatment.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histology</strong> – Treatment is not indicated for asymptomatic individuals who undergo cervical biopsy for the evaluation of cervical intraepithelial neoplasia and are found to have histologic, but no clinical, evidence of cervicitis. Histologic inflammation is a poor indicator of a specific infection [<a href="#rid2">2</a>]. Although follicular cervicitis (lymphoid follicles beneath the epithelium) suggests, but is not pathognomonic of, chlamydial cervicitis [<a href="#rid5">5,44,45</a>], follicular cervicitis can also occur with noninfectious cervicitis. Diagnostic testing is needed in these cases to confirm or exclude a specific infection and to guide treatment. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytology</strong> – Inflammation on cervical cytology is not an indication for treatment. The presence of a few lymphocytes on cytologic smears is normal and should not be misdiagnosed as inflammation.</p><p></p><p class="headingAnchor" id="H3873700099"><span class="h2">Sexual partners</span><span class="headingEndMark"> — </span>Sexual partners of patients with chlamydia, gonorrhea, or trichomoniasis should be treated for the STI for which the patient received treatment. The optimal approach for sexual partners of individuals with confirmed M. genitalium infection is less clear. (See  <a class="medical medical_review" href="/z/d/html/83202.html" rel="external">"<i>Mycoplasma genitalium</i> infection", section on 'Partner management'</a>.)</p><p>To avoid reinfection, patients and their sexual partners should abstain from sexual intercourse until antibiotic therapy is completed (seven days after a single-dose regimen or after completion of a seven-day regimen) and symptoms have resolved [<a href="#rid3">3</a>]. (See <a class="local">'Targeted treatment of specific infections'</a> above.)</p><p class="headingAnchor" id="H4258067330"><span class="h2">Other populations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnant individuals</strong> – Diagnosis of cervicitis for pregnant persons is the same as above [<a href="#rid3">3</a>]. For treatment, <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> is preferred as <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> and fluoroquinolones are generally avoided in pregnancy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Individuals living with HIV</strong> – No data suggest different treatment for this patient population [<a href="#rid3">3</a>]. Cervicitis is thought to increase HIV-1 shedding from the cervix in the presence of cervicitis; treatment reduces shedding. Women with HIV were observed to have a high prevalence of <em>M. genitalium</em> (7.4 percent), which was associated with increased cytokines in cervicovaginal fluid [<a href="#rid46">46</a>]. In this population, treatment that covers for <em>M. genitalium</em> may be important in decreasing the risk of HIV transmission to an HIV-negative sexual partner. (See <a class="local">'Targeted treatment of specific infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Individuals with a foreign body/substance</strong> – For individuals with cervicitis that appears to be associated with a foreign body/substance, removal or avoidance of the foreign body/substance will often lead to resolution of inflammation. Therefore, chemical douches, vaginal contraceptives and deodorants, and pessaries should be discontinued and the patient reevaluated for therapeutic response. For those with mild to moderate symptoms and no purulent discharge, we remove the foreign body/substance and assess for symptom resolution before we treat with an antimicrobial drug such as topical <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> or <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>. For patients with severe purulent vaginitis associated with a foreign body, we remove the foreign body and treat with antibiotic treatment (oral <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> or topical metronidazole or clindamycin), although there are no data to guide the choice of drug therapy. Unusual examples of retained foreign bodies an IUD with confirmed actinomyces infection or retained vaginal cerclage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Individuals with an intrauterine device (IUD)</strong> – Individuals with an IUD who also develop symptoms or signs of cervicitis can generally be treated for the cervicitis with the IUD in place. One exception is confirmed infection with actinomyces; in this setting the IUD is removed to facilitate treatment. If a patient has chronic cervicitis and other causes have been excluded, it may be reasonable to remove the IUD to assess for symptom resolution. In one trial of 132 women with <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">copper IUDs</a> and cervicitis, the cervicitis resolved in 131 women after treatment with daily oral estriol 0.25 mg for three months [<a href="#rid47">47,48</a>]. However, oral estriol is not universally available, and empiric estrogen treatment is not advised in the absence of established indications. Patients with an IUD and PID are treated as per PID guidelines [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/5422.html" rel="external">"Intrauterine contraception: Management of side effects and complications", section on 'Infection and/or pelvic inflammatory disease'</a>.)</p><p></p><p class="headingAnchor" id="H13"><span class="h1">COUNSELING AND FOLLOW-UP</span><span class="headingEndMark"> — </span>Symptoms of cervicitis typically respond within a week or two of treatment. In general, patients and their sexual partners should abstain from sexual intercourse until treatment has been completed (seven days after a single-dose regimen or after completion of a seven-day regimen) [<a href="#rid3">3</a>].</p><p>Follow-up visits can be scheduled to confirm resolution of symptoms and discuss test results. Individuals with confirmed chlamydia, gonorrhea, or trichomonas infections should be retested three months after initial treatment because of high rates of reinfection [<a href="#rid3">3</a>]. Additionally, they should be offered counseling and testing for HIV and syphilis. (See  <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H21041321"><span class="h1">RECURRENT OR PERSISTENT DISEASE</span><span class="headingEndMark"> — </span>Cervicitis can persist despite repeated courses of antimicrobial therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach</strong> – Individuals who present with recurrent symptoms are reevaluated for possible re-exposure or treatment failure [<a href="#rid3">3</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We repeat the diagnostic work-up and ensure that (1) nucleic acid amplification testing (NAAT) is negative for detection of <em>C. trachomatis</em> and <em>N. gonorrhoeae</em>, and (2) sexual partners have been appropriately treated, and (3) the patient has not been re-exposed to potential pathogens (ie, new sexual partner).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diagnostic testing is performed for trichomoniasis and bacterial vaginosis (BV). Some experts also suggest testing for <em>M. genitalium</em>, if available.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exposure to potential intravaginal irritants (lubricants, spermicides, douching) is reassessed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If possible, sexual partners should be examined and tested for chlamydia and gonorrhea, particularly if they were not treated presumptively at the time of the patient's initial treatment for cervicitis. (See <a class="local">'Other populations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the above steps are completed and no cause of the persistent cervicitis has been identified, treatment can be considered for <em>M. genitalium</em>, as discussed below, particularly if NAAT for this infection is not available.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with recurrent or persistent cervicitis reflect a particular challenge. Those without a clear etiology of any sort whose symptoms persist for more than three months are diagnosed with chronic cervicitis. (See <a class="local">'Chronic cervicitis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>M. genitalium</em></strong> –The role of <em>M. genitalium</em> in persistent cervicitis is unclear [<a href="#rid3">3</a>]. <em>M. genitalium</em> is very difficult to culture; most studies have used nucleic acid amplification (polymerase chain reaction or transcription-mediated amplification) for identification [<a href="#rid2">2,9,35,36</a>]. <em>M. genitalium</em> NAAT testing should be performed in patients with persistent cervicitis who have not yet been tested. Those who test positive receive targeted treatment. If <em>M. genitalium</em> NAAT cannot be performed, and thus resistance testing is not known, and the patient has persistent cervicitis despite prior antibiotic treatment, it is reasonable to treat empirically for <em>M. genitalium</em>. Treatment approaches for this population are discussed in related content.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/83202.html" rel="external">"<i>Mycoplasma genitalium</i> infection", section on 'Empiric M. genitalium therapy for selected syndromic treatment failures'</a>.)</p><p></p><p class="headingAnchor" id="H112758137"><span class="h1">CHRONIC CERVICITIS</span><span class="headingEndMark"> — </span>The term "chronic" in this context generally refers to patients in whom the usual infectious causes of acute cervicitis described above have been treated or excluded, yet abnormal physical signs persist for at least three months. A minority of patients have persistent mucopurulent endocervical discharge. Chronic cervicitis usually has a noninfectious source [<a href="#rid32">32</a>]. In individuals with chronic cervicitis, the cervical mucosa is hyperemic and may be ulcerated. Obstruction of the mucous glands may result in formation of nabothian cysts. (See  <a class="medical medical_review" href="/z/d/html/5428.html" rel="external">"Benign cervical lesions and congenital anomalies of the cervix", section on 'Nabothian cysts'</a>.)</p><p>Patients with chronic cervicitis who fail to respond to antibiotics are a therapeutic challenge; there is no standardized approach for these patients [<a href="#rid32">32</a>]. Some may respond to two doses of depot medroxyprogesterone or cauterization of the bleeding points with <a class="drug drug_general" data-topicid="9888" href="/z/d/drug information/9888.html" rel="external">silver nitrate</a>, which can be applied repeatedly every two weeks until the cervicitis improves or fails to show a clinical response. As a last resort, electrocautery, laser, or shallow loop excision can successfully reduce persistent mucopurulent discharge unresponsive to other measures and for which an etiology has not been determined [<a href="#rid5">5</a>]. It is imperative that malignancy be excluded ( pap smear and/or by biopsy) before any ablative treatment is undertaken.</p><p class="headingAnchor" id="H279302655"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111582.html" rel="external">"Society guideline links: Sexually transmitted infections"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/109421.html" rel="external">"Society guideline links: Bacterial vaginosis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/111629.html" rel="external">"Society guideline links: Gynecologic infectious diseases (non-sexually transmitted)"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and etiologies</strong> – Cervicitis refers to inflammation of the uterine cervix that primarily affects the columnar epithelial cells of the endocervical glands. The squamous epithelium of the ectocervix can also be involved. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infectious</strong> – Sexually transmitted infections (STIs) are the most common cause with <em>Neisseria gonorrhoeae</em> and <em>Chlamydia trachomatis</em> being the two most common infections. It is uncertain how much <em>Mycoplasma genitalium</em> contributes to cervicitis, but this organism is likely responsible for a substantial minority of cases. (See <a class="local">'Infectious etiologies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Noninfectious etiologies</strong> – In cases where no infection is identified, cervicitis is usually caused by mechanical or chemical irritation such as from a diaphragm or vaginal douche, respectively. Often, there may be no clearly identified cause. (See <a class="local">'Noninfectious causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The presenting symptoms are purulent or mucopurulent discharge and/or easily induced bleeding (friability) from the endocervix when touched with an endocervical swab. Associated symptoms include abnormal vaginal discharge, dysuria/urinary frequency, and intermenstrual or postcoital bleeding. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Diagnostic evaluation includes a history, physical examination, and testing for potential causative organisms (ie, chlamydia, gonorrhea, <em>Trichomonas vaginalis,</em> and bacterial vaginosis)  (<a class="graphic graphic_algorithm graphicRef138432" href="/z/d/graphic/138432.html" rel="external">algorithm 1</a>). (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Cervicitis is a clinical diagnosis is based upon the presence of mucopurulent cervical discharge or friability. Infectious causes may be diagnosed by specific laboratory testing. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– For individuals with physical examination findings of cervicitis, we suggest empiric therapy rather than treatment based on risk factors for STI acquisition or targeted test results. (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We offer treatment for chlamydia and gonorrhea infection as these are the most common infectious etiologies. As data directly comparing the strategies are lacking, all approaches are reasonable and patient preferences influence the decision.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See <a class="local">'Empiric therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See <a class="local">'Treatment based on STI risk'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See <a class="local">'Targeted treatment of specific infections'</a> above.)</p><p></p><p class="bulletIndent1">Individuals with clinically diagnosed cervicitis are offered treatment regardless of symptomatology. The goals of treatment are relief of symptoms and prevention of infection of the upper genital tract.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sexual partners</strong> – Treatment, follow-up, and management of sexual partners depends upon the test results. Treatment of sexual partners is indicated for patients with chlamydia, gonorrhea, or trichomonas infections. (See <a class="local">'Sexual partners'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent symptoms</strong> – Individuals who present with recurrent symptoms are reevaluated for possible re-exposure or treatment failure. We treat patients with persistent cervicitis for presumed <em>M. genitalium</em> if they have not already been treated for this agent and NAAT-based testing has not excluded this organism. (See <a class="local">'Recurrent or persistent disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic cervicitis</strong> – Chronic cervicitis refers to those in whom the usual infectious causes of acute cervicitis have been treated or excluded, yet abnormal physical signs persist for at least three months. A minority of patients have persistent mucopurulent endocervical discharge. Chronic cervicitis usually has a noninfectious source. (See <a class="local">'Chronic cervicitis'</a> above.)</p><p></p><p class="headingAnchor" id="H387692590"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Dr. Jeanne Marrazzo, MD, MPH, FACP, FIDSA who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Manhart LE, Critchlow CW, Holmes KK, et al. Mucopurulent cervicitis and Mycoplasma genitalium. J Infect Dis 2003; 187:650.</a></li><li><a class="nounderline abstract_t">Marrazzo JM, Martin DH. Management of women with cervicitis. Clin Infect Dis 2007; 44 Suppl 3:S102.</a></li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Falk L, Fredlund H, Jensen JS. Signs and symptoms of urethritis and cervicitis among women with or without Mycoplasma genitalium or Chlamydia trachomatis infection. Sex Transm Infect 2005; 81:73.</a></li><li><a class="nounderline abstract_t">Nyirjesy P. Nongonococcal and Nonchlamydial Cervicitis. Curr Infect Dis Rep 2001; 3:540.</a></li><li><a class="nounderline abstract_t">Taylor SN, Lensing S, Schwebke J, et al. Prevalence and treatment outcome of cervicitis of unknown etiology. Sex Transm Dis 2013; 40:379.</a></li><li><a class="nounderline abstract_t">Rodrigues MM, Fernandes PÁ, Haddad JP, et al. Frequency of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis and Ureaplasma species in cervical samples. J Obstet Gynaecol 2011; 31:237.</a></li><li><a class="nounderline abstract_t">Gaydos C, Maldeis NE, Hardick A, et al. Mycoplasma genitalium as a contributor to the multiple etiologies of cervicitis in women attending sexually transmitted disease clinics. Sex Transm Dis 2009; 36:598.</a></li><li><a class="nounderline abstract_t">Bjartling C, Osser S, Persson K. Mycoplasma genitalium in cervicitis and pelvic inflammatory disease among women at a gynecologic outpatient service. Am J Obstet Gynecol 2012; 206:476.e1.</a></li><li><a class="nounderline abstract_t">Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis 2015; 61:418.</a></li><li><a class="nounderline abstract_t">Paraskevaides EC, Wilson MC. Fatal disseminated intravascular coagulation secondary to streptococcal cervicitis. Eur J Obstet Gynecol Reprod Biol 1988; 29:39.</a></li><li><a class="nounderline abstract_t">Marrazzo JM, Wiesenfeld HC, Murray PJ, et al. Risk factors for cervicitis among women with bacterial vaginosis. J Infect Dis 2006; 193:617.</a></li><li><a class="nounderline abstract_t">Samantaray S, Parida G, Rout N, et al. Cytologic detection of tuberculous cervicitis: a report of 7 cases. Acta Cytol 2009; 53:594.</a></li><li><a class="nounderline abstract_t">Singh S, Gupta V, Modi S, et al. Tuberculosis of uterine cervix: a report of two cases with variable clinical presentation. Trop Doct 2010; 40:125.</a></li><li><a class="nounderline abstract_t">Mukherjee S, Nagarsenkar A, Chandra S, et al. Amoebic cervicitis mimicking posterior wall fibroid: a rare presentation. J Microbiol Immunol Infect 2014; 47:354.</a></li><li><a class="nounderline abstract_t">Abou M, Dällenbach P. Acute cervicitis and vulvovaginitis may be associated with Cytomegalovirus. BMJ Case Rep 2013; 2013.</a></li><li><a class="nounderline abstract_t">Schwebke JR, Weiss HL. Interrelationships of bacterial vaginosis and cervical inflammation. Sex Transm Dis 2002; 29:59.</a></li><li><a class="nounderline abstract_t">Mitchell L, King M, Brillhart H, Goldstein A. Cervical Ectropion May Be a Cause of Desquamative Inflammatory Vaginitis. Sex Med 2017; 5:e212.</a></li><li><a class="nounderline abstract_t">Gorgos LM, Sycuro LK, Srinivasan S, et al. Relationship of Specific Bacteria in the Cervical and Vaginal Microbiotas With Cervicitis. Sex Transm Dis 2015; 42:475.</a></li><li><a class="nounderline abstract_t">Uusküla A, Raukas E. Atypical genital herpes: report of five cases. Scand J Infect Dis 2004; 36:37.</a></li><li><a class="nounderline abstract_t">Yliskoski M, Tervahauta A, Saarikoski S, et al. Clinical course of cervical human papillomavirus lesions in relation to coexistent cervical infections. Sex Transm Dis 1992; 19:137.</a></li><li><a class="nounderline abstract_t">Marrazzo JM. Mucopurulent cervicitis: no longer ignored, but still misunderstood. Infect Dis Clin North Am 2005; 19:333.</a></li><li><a class="nounderline abstract_t">McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007; 195:698.</a></li><li><a class="nounderline abstract_t">Nugent RP, Hillier SL. Mucopurulent cervicitis as a predictor of chlamydial infection and adverse pregnancy outcome. The Investigators of the Johns Hopkins Study of Cervicitis and Adverse Pregnancy Outcome. Sex Transm Dis 1992; 19:198.</a></li><li><a class="nounderline abstract_t">Paavonen J, Critchlow CW, DeRouen T, et al. Etiology of cervical inflammation. Am J Obstet Gynecol 1986; 154:556.</a></li><li><a class="nounderline abstract_t">Kletzel HH, Rotem R, Barg M, et al. Ureaplasma urealyticum: the Role as a Pathogen in Women's Health, a Systematic Review. Curr Infect Dis Rep 2018; 20:33.</a></li><li><a class="nounderline abstract_t">Lukic A, Canzio C, Patella A, et al. Determination of cervicovaginal microorganisms in women with abnormal cervical cytology: the role of Ureaplasma urealyticum. Anticancer Res 2006; 26:4843.</a></li><li><a class="nounderline abstract_t">Taylor SN. Cervicitis of unknown etiology. Curr Infect Dis Rep 2014; 16:409.</a></li><li><a class="nounderline abstract_t">Baithun M, Freeman-Wang T, Chowdary P, Kadir RA. Ligneous cervicitis and endometritis: A gynaecological presentation of congenital plasminogen deficiency. Haemophilia 2018; 24:359.</a></li><li><a class="nounderline abstract_t">Oliveto JM, Muinov L. Cystic Cervicitis: A Case Report and Literature Review of Cystic Cervical Lesions. J Comput Assist Tomogr 2016; 40:564.</a></li><li><a class="nounderline abstract_t">Kim MJ, Kim NR, Cho HY, et al. Differential diagnostic features of small cell carcinoma in the uterine cervix. Diagn Cytopathol 2008; 36:618.</a></li><li><a class="nounderline abstract_t">Mattson SK, Polk JP, Nyirjesy P. Chronic Cervicitis: Presenting Features and Response to Therapy. J Low Genit Tract Dis 2016; 20:e30.</a></li><li><a class="nounderline abstract_t">Marrazzo JM, Handsfield HH, Whittington WL. Predicting chlamydial and gonococcal cervical infection: implications for management of cervicitis. Obstet Gynecol 2002; 100:579.</a></li><li><a class="nounderline abstract_t">Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992; 116:433.</a></li><li><a class="nounderline abstract_t">Huppert JS, Mortensen JE, Reed JL, et al. Mycoplasma genitalium detected by transcription-mediated amplification is associated with Chlamydia trachomatis in adolescent women. Sex Transm Dis 2008; 35:250.</a></li><li><a class="nounderline abstract_t">Short VL, Totten PA, Ness RB, et al. Clinical presentation of Mycoplasma genitalium Infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease. Clin Infect Dis 2009; 48:41.</a></li><li><a class="nounderline abstract_t">Reichman O, Sobel J. Desquamative inflammatory vaginitis. Best Pract Res Clin Obstet Gynaecol 2014; 28:1042.</a></li><li><a class="nounderline abstract_t">Sobel JD. Desquamative inflammatory vaginitis: a new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. Am J Obstet Gynecol 1994; 171:1215.</a></li><li><a class="nounderline abstract_t">Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis 2008; 35:946.</a></li><li><a class="nounderline abstract_t">St Cyr S, Barbee L, Workowski KA, et al. Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1911.</a></li><li><a class="nounderline abstract_t">Kirkcaldy RD, Kidd S, Weinstock HS, et al. Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006-June 2012. Sex Transm Infect 2013; 89 Suppl 4:iv5.</a></li><li><a class="nounderline abstract_t">Whittington WL, Kent C, Kissinger P, et al. Determinants of persistent and recurrent Chlamydia trachomatis infection in young women: results of a multicenter cohort study. Sex Transm Dis 2001; 28:117.</a></li><li><a class="nounderline abstract_t">Chandeying V, Sutthijumroon S, Tungphaisal S. Evaluation of ofloxacin in the treatment of mucopurulent cervicitis: response of chlamydia-positive and chlamydia-negative forms. J Med Assoc Thai 1989; 72:331.</a></li><li><a class="nounderline abstract_t">Dunlop EM, Garner A, Darougar S, et al. Colposcopy, biopsy, and cytology results in women with chlamydial cervicitis. Genitourin Med 1989; 65:22.</a></li><li><a class="nounderline abstract_t">Paavonen J, Vesterinen E, Meyer B, Saksela E. Colposcopic and histologic findings in cervical chlamydial infection. Obstet Gynecol 1982; 59:712.</a></li><li><a class="nounderline abstract_t">Dehon PM, Hagensee ME, Sutton KJ, et al. Histological Evidence of Chronic Mycoplasma genitalium-Induced Cervicitis in HIV-Infected Women: A Retrospective Cohort Study. J Infect Dis 2016; 213:1828.</a></li><li><a class="nounderline abstract_t">Rubinstein E. The copper-7 device in chronic and IUD-induced acute cervicitis treated with oral estriol. Contraception 1974; 10:673.</a></li><li><a class="nounderline abstract_t">Erol O, Simavlı S, Derbent AU, et al. The impact of copper-containing and levonorgestrel-releasing intrauterine contraceptives on cervicovaginal cytology and microbiological flora: a prospective study. Eur J Contracept Reprod Health Care 2014; 19:187.</a></li></ol></div><div id="topicVersionRevision">Topic 5460 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12599082" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mucopurulent cervicitis and Mycoplasma genitalium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17342663" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of women with cervicitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15681728" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Signs and symptoms of urethritis and cervicitis among women with or without Mycoplasma genitalium or Chlamydia trachomatis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11722812" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Nongonococcal and Nonchlamydial Cervicitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23588127" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence and treatment outcome of cervicitis of unknown etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21417648" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Frequency of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis and Ureaplasma species in cervical samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19704398" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mycoplasma genitalium as a contributor to the multiple etiologies of cervicitis in women attending sexually transmitted disease clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22483084" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mycoplasma genitalium in cervicitis and pelvic inflammatory disease among women at a gynecologic outpatient service.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25900174" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3066659" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fatal disseminated intravascular coagulation secondary to streptococcal cervicitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16453256" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Risk factors for cervicitis among women with bacterial vaginosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19798892" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cytologic detection of tuberculous cervicitis: a report of 7 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20305116" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Tuberculosis of uterine cervix: a report of two cases with variable clinical presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22743593" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Amoebic cervicitis mimicking posterior wall fibroid: a rare presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23606387" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Acute cervicitis and vulvovaginitis may be associated with Cytomegalovirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773880" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Interrelationships of bacterial vaginosis and cervical inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28460993" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cervical Ectropion May Be a Cause of Desquamative Inflammatory Vaginitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26267872" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Relationship of Specific Bacteria in the Cervical and Vaginal Microbiotas With Cervicitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15000557" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Atypical genital herpes: report of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1326128" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical course of cervical human papillomavirus lesions in relation to coexistent cervical infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15963875" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mucopurulent cervicitis: no longer ignored, but still misunderstood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17262712" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1411834" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mucopurulent cervicitis as a predictor of chlamydial infection and adverse pregnancy outcome. The Investigators of the Johns Hopkins Study of Cervicitis and Adverse Pregnancy Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3485379" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Etiology of cervical inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29959546" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Ureaplasma urealyticum: the Role as a Pathogen in Women's Health, a Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17214350" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Determination of cervicovaginal microorganisms in women with abnormal cervical cytology: the role of Ureaplasma urealyticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24859465" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cervicitis of unknown etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29436075" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Ligneous cervicitis and endometritis: A gynaecological presentation of congenital plasminogen deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27331927" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cystic Cervicitis: A Case Report and Literature Review of Cystic Cervical Lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18677758" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Differential diagnostic features of small cell carcinoma in the uterine cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27243142" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Chronic Cervicitis: Presenting Features and Response to Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12220782" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Predicting chlamydial and gonococcal cervical infection: implications for management of cervicitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1310837" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18490867" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mycoplasma genitalium detected by transcription-mediated amplification is associated with Chlamydia trachomatis in adolescent women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19025498" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical presentation of Mycoplasma genitalium Infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25132275" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Desquamative inflammatory vaginitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7977522" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Desquamative inflammatory vaginitis: a new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18685546" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332296" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24243881" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006-June 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11234786" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Determinants of persistent and recurrent Chlamydia trachomatis infection in young women: results of a multicenter cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2778422" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Evaluation of ofloxacin in the treatment of mucopurulent cervicitis: response of chlamydia-positive and chlamydia-negative forms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2921049" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Colposcopy, biopsy, and cytology results in women with chlamydial cervicitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7078909" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Colposcopic and histologic findings in cervical chlamydial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26783349" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Histological Evidence of Chronic Mycoplasma genitalium-Induced Cervicitis in HIV-Infected Women: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4614936" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The copper-7 device in chronic and IUD-induced acute cervicitis treated with oral estriol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24738915" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The impact of copper-containing and levonorgestrel-releasing intrauterine contraceptives on cervicovaginal cytology and microbiological flora: a prospective study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
